State Board of Administration of Florida Retirement System raised its stake in Cerus Corp. (NASDAQ:CERS) by 24.0% during the second quarter, Holdings Channel reports. The institutional investor owned 36,846 shares of the company’s stock after buying an additional 7,140 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Cerus Corp. were worth $230,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in CERS. DekaBank Deutsche Girozentrale boosted its position in Cerus Corp. by 15.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 48,000 shares of the company’s stock worth $300,000 after buying an additional 6,500 shares during the period. California State Teachers Retirement System boosted its position in Cerus Corp. by 4.9% in the second quarter. California State Teachers Retirement System now owns 211,846 shares of the company’s stock worth $1,322,000 after buying an additional 9,800 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in Cerus Corp. by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,559,771 shares of the company’s stock worth $15,179,000 after buying an additional 15,881 shares during the period. Renaissance Technologies LLC purchased a new position in Cerus Corp. during the first quarter worth $110,000. Finally, BlackRock Fund Advisors boosted its position in Cerus Corp. by 0.7% in the first quarter. BlackRock Fund Advisors now owns 3,730,957 shares of the company’s stock worth $22,125,000 after buying an additional 24,166 shares during the period. Institutional investors own 67.04% of the company’s stock.
Cerus Corp. (NASDAQ:CERS) traded up 1.36% during mid-day trading on Tuesday, reaching $5.22. 108,073 shares of the company were exchanged. The stock’s 50-day moving average price is $6.12 and its 200-day moving average price is $6.21. Cerus Corp. has a 1-year low of $4.27 and a 1-year high of $7.64. The stock’s market capitalization is $536.14 million.
Cerus Corp. (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. Cerus Corp. had a negative return on equity of 73.14% and a negative net margin of 189.29%. The company had revenue of $9.25 million for the quarter, compared to analysts’ expectations of $8.88 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. The firm’s revenue was up 4.8% on a year-over-year basis. On average, equities research analysts anticipate that Cerus Corp. will post ($0.68) EPS for the current fiscal year.
A number of research firms have recently commented on CERS. Robert W. Baird set a $10.00 price target on shares of Cerus Corp. and gave the stock a “buy” rating in a report on Saturday, August 6th. FBR & Co restated a “buy” rating on shares of Cerus Corp. in a report on Monday, July 11th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Cerus Corp. in a report on Monday, June 20th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Cerus Corp. in a report on Thursday, July 7th. Finally, Zacks Investment Research cut shares of Cerus Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $9.10.
In other news, CFO Kevin Dennis Green sold 17,150 shares of Cerus Corp. stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total transaction of $116,620.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 6.60% of the company’s stock.
About Cerus Corp.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.